Recombinant allergens: What does the future hold?

Journal of Allergy and Clinical Immunology

Volumn 127, Issue 4, 2011, Pages 860-864

  Valenta, Rudolf ^a,b   Niespodziana, Katarzyna ^b   Focke Tejkl, Margit ^a   Marth, Katharina ^a   Huber, Hans ^c   Neubauer, Angela ^c   Niederberger, Verena ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c BIOMAY AG   (Austria)

Author keywords

allergen specific immunotherapy; Allergy; recombinant allergen

Indexed keywords

BIRCH POLLEN EXTRACT; EPITOPE; HOUSE DUST ALLERGEN; HYBRID PROTEIN; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G4; NATURAL BIRCH POLLEN ALLERGEN; OLIVE POLLEN ALLERGEN; RECOMBINANT ALLERGEN; RECOMBINANT BIRCH POLLEN ALLERGEN; RECOMBINANT PEANUT ALLERGEN; RECOMBINANT VACCINE; RECOMBINANT WILD TYPE TIMOTHY GRASS POLLEN ALLERGEN; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS VECTOR;

ALLERGIC REACTION; ANAPHYLAXIS; ANTIBODY PRODUCTION; ARTICLE; CLINICAL TRIAL (TOPIC); DRUG DOSE ESCALATION; DRUG DOSE INCREASE; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; MAINTENANCE THERAPY; MORNING DOSAGE; NONHUMAN; PEANUT ALLERGY; POLLEN ALLERGY; PRIORITY JOURNAL; RECOMBINANT DNA TECHNOLOGY; SKIN TEST; VACCINATION;

ALLERGENS; ANIMALS; DESENSITIZATION, IMMUNOLOGIC; HUMANS; HYPERSENSITIVITY; RECOMBINANT PROTEINS; VACCINES;

EID: 79953651817     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2011.02.016     Document Type: Article

References (24)

1. L. Noon Prophylactic inoculation against hay fever Lancet 1 1911 1572 1573
2. R.A. Cooke, J.H. Barnard, S. Hebald, and A. Stull Serological evidence of immunity with coexisting sensitization in a type of human allergy J Exp Med 62 1935 733 750
3. M. Larché, C.A. Akdis, and R. Valenta Immunological mechanisms of allergen-specific immunotherapy Nat Rev Immunol 6 2006 761 771 (Pubitemid 44453462)
4. R. Valenta, F. Ferreira, M. Focke-Tejkl, B. Linhart, V. Niederberger, and I. Swoboda From allergen genes to allergy vaccines Annu Rev Immunol 28 2010 211 241
5. M. Focke, I. Swoboda, K. Marth, and R. Valenta Developments in allergen-specific immunotherapy: from allergen extracts to allergy vaccines bypassing allergen-specific immunoglobulin E and T cell reactivity Clin Exp Allergy 40 2010 385 397
6. B. Linhart, A. Hartl, B. Jahn-Schmid, P. Verdino, W. Keller, and M.T. Krauth A hybrid molecule resembling the epitope spectrum of grass pollen for allergy vaccination J Allergy Clin Immunol 115 2005 1010 1016 (Pubitemid 40616216)
7. D.G. Marsh, L.M. Lichtenstein, and D.H. Campbell Studies on "allergoids" prepared from naturally occurring allergens. I. Assay of allergenicity and antigenicity of formalinized rye group I component Immunology 18 1970 705 722
8. R. Valenta The future of antigen-specific immunotherapy of allergy Nat Rev Immunol 2 2002 446 453 (Pubitemid 37328752)
9. V. Niederberger, F. Horak, S. Vrtala, S. Spitzauer, M.T. Krauth, and P. Valent Vaccination with genetically engineered allergens prevents progression of allergic disease Proc Natl Acad Sci U S A 101 suppl 2 2004 14677 14682 (Pubitemid 39346742)
10. L. Klimek, C. Bachert, C. Doemer, H. Meyer, and A. Narkus Specific immunotherapy with recombinant birch pollen allergen rBet v 1-FV is clinically efficacious Allergy Clin Immunol Int suppl 1 2005 15
11. Rak S. Clinical results with a hypoallergenic recombinant birch pollen allergen derivative. Presented at: the 27th Congress of the European Academy for Allergology and Clinical Immunology, June 6-10, 2009, Warsaw, Poland.
12. M. Jutel, L. Jaeger, R. Suck, H. Meyer, H. Fiebig, and O. Cromwell Allergen-specific immunotherapy with recombinant grass pollen allergens J Allergy Clin Immunol 116 2005 608 613 (Pubitemid 41267135)
13. G. Pauli, T.H. Larsen, S. Rak, F. Horak, E. Pastorello, and R. Valenta Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis J Allergy Clin Immunol 122 2008 951 960
14. L. Winther, L.K. Poulsen, B. Robin, M. Mélac, and H. Malling Safety and Tolerability of Recombinant Bet v 1 (rBet v 1) tablets in sublingual immunotherapy (SLIT) J Allergy Clin Immunol 123 suppl 2009 S215
15. I. Pree, M.H. Shamji, I. Kimber, R. Valenta, S.R. Durham, and V. Niederberger Inhibition of CD-23-dependent facilitated allergen binding to B cells following vaccination with genetically modified hypoallergenic Bet v 1 molecules Clin Exp Allergy 40 2010 1346 1352
16. A. Purohit, V. Niederberger, M. Kronqvist, F. Horak, R. Gronneberg, and R. Suck Clinical effects of immunotherapy with genetically modified recombinant birch pollen Bet v 1 derivatives Clin Exp Allergy 38 2008 1514 1525
17. R. Campana, N. Mothes, I. Rauter, S. Vrtala, R. Reininger, and M. Focke-Tejkl Non-IgE-mediated chronic allergic skin inflammation revealed with rBet v 1 fragments J Allergy Clin Immunol 121 2008 528 530
18. M. Focke, V. Mahler, T. Ball, W.R. Sperr, Y. Majlesi, and P. Valent Nonanaphylactic synthetic peptides derived from B cell epitopes of the major grass pollen allergen, Phl p 1, for allergy vaccination FASEB J 15 2001 2042 2044
19. M. Focke, B. Linhart, A. Hartl, U. Wiedermann, W.R. Sperr, and P. Valent Non-anaphylactic surface-exposed peptides of the major birch pollen allergen, Bet v 1, for preventive vaccination Clin Exp Allergy 34 2004 1525 1533 (Pubitemid 39389328)
20. D.H. Katz, W.E. Paul, E.A. Goidl, and B. Benacerraf Carrier function in anti-hapten immune responses. I. Enhancement of primary and secondary anti-hapten antibody responses by carrier preimmunization J Exp Med 132 1970 261 282
21. Twaroch T, Focke-Tejkl M, Civaj V, Weber M, Balic N, Mari A, et al. Carrier-bound, non-allergenic Ole e 1 peptides for vaccination against olive pollen allergy. J Allergy Clin Immunol. In press 2011.
22. T.M. Kundig, G. Senti, G. Schnetzler, C. Wolf, B.M. Prinz Vavricka, and A. Fulurija Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults J Allergy Clin Immunol 117 2006 1470 1476 (Pubitemid 43795737)
23. J. Edlmayr, K. Niespodziana, B. Linhart, M. Focke-Tejkl, K. Westritschnig, and S. Scheiblhofer A combination vaccine for allergy and rhinovirus infections based on rhinovirus-derived surface protein VP1 and a nonallergenic peptide of the major timothy grass pollen allergen Phl p 1 J Immunol 182 2009 6298 6306
24. Niespodziana K. A hypoallergenic cat vaccine based on Fel d 1-derived peptides fused to hepatitis B PreS. J Allergy Clin Immunol. In press 2011.